KRT13 KO cell line available to order. KO validated by Next Generation Sequencing, Western blot. Free of charge wild type control provided. Knockout achieved by CRISPR/Cas9 X = 5 bp deletion Frameshift: 100%.
Images
Key facts
- Cell type
- A-431
- Species or organism
- Human
- Tissue
- Skin
- Form
- Liquid
- Knockout validation
- Next Generation Sequencing, Western blot
- Mutation description
- Knockout achieved by CRISPR/Cas9 X = 5 bp deletion Frameshift: 100%
Alternative names
47 kDa cytokeratin, CK-13, Cytokeratin-13, K13, K1C13_HUMAN, KRT13, Ka13, Keratin, Keratin-13, Krt-1.13, Krt1-13, MGC161462, MGC3781, Type I keratin Ka13, WSN2, keratin type I cytoskeletal 13, type I cytoskeletal 13
Recommended products
KRT13 KO cell line available to order. KO validated by Next Generation Sequencing, Western blot. Free of charge wild type control provided. Knockout achieved by CRISPR/Cas9 X = 5 bp deletion Frameshift: 100%.
Key facts
- Cell type
- A-431
- Species or organism
- Human
- Tissue
- Skin
- Form
- Liquid
- Knockout validation
- Next Generation Sequencing, Western blot
- Mutation description
- Knockout achieved by CRISPR/Cas9 X = 5 bp deletion Frameshift: 100%
- Disease
- Epidermoid Carcinoma
- Concentration
Properties
- Gene name
- KRT13
- Gene editing type
- Knockout
- Gene editing method
- CRISPR technology
- Knockout validation
- Next Generation Sequencing, Western blot
Quality control
- STR analysis
- CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX
Cell culture
- Biosafety level
- EU: 1 US: 1
- Adherent/suspension
- Adherent
- Gender
- Female
Handling procedures
- Initial handling guidelines
Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.
1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.- Subculture guidelines
- All seeding densities should be based on cell counts gained by established methods.
- A guide seeding density of 2x104 cells/cm2 is recommended.
- Cells should be passaged when they have achieved 80-90% confluence.
- Culture medium
- DMEM (High Glucose) + 10% FBS
- Cryopreservation medium
- Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.
Storage
- Shipped at conditions
- Dry Ice
- Appropriate short-term storage conditions
- -196°C
- Appropriate long-term storage conditions
- -196°C
Notes
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.
Supplementary info
- This supplementary information is collated from multiple sources and compiled automatically.
- Activity summary
Cytokeratin 13 also known as KRT13 or CK13 is a type I intermediate filament protein weighing approximately 44 kDa. It is one of the cytokeratin types that plays a critical role in the mechanical stability and integrity of epithelial cells. Cytokeratin 13 is expressed in the stratified squamous epithelium particularly in the upper layers of non-cornified epithelia which include the esophagus tongue and cervix. This protein forms heteropolymers with type II keratins contributing to the cytoskeletal filament network within epithelial cells.
- Biological function summary
This protein participates in maintaining the structural framework and dynamics within epithelial tissues. As part of the cytoskeletal complex cytokeratin 13 supports cellular resilience against mechanical stress. It interacts with other cytokeratins contributing to the formation of a robust keratin filament network essential for epithelial cell function and differentiation. Its expression and regulation are key to the homeostasis of the tissues where it is found ensuring proper cell division and tissue integrity.
- Pathways
Cytokeratin 13 integrates into epithelial cell differentiation and repair processes. It is involved in the epithelial-mesenchymal transition (EMT) pathway important for tissue development wound healing and cancer metastasis. During the EMT process cytokeratin 13 often works alongside proteins like E-cadherin and Vimentin mediating changes in epithelial cell architecture and polarity. This modulation is essential for cellular plasticity and response to environmental cues.
- Associated diseases and disorders
Cytokeratin 13 has associations with certain epithelial tissue abnormalities such as oral squamous cell carcinoma and a subgroup of inherited blistering diseases like epidermolysis bullosa. In oral squamous cell carcinoma dysregulation of cytokeratin 13 expression may indicate tumor progression and metastasis. In epidermolysis bullosa mutations affecting keratin interactions including those with other keratins like cytokeratin 14 can lead to fragile skin and mucosal surfaces resulting in increased susceptibility to physical damage and impaired healing.
Product promise
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
4 product images
Western blot - Human KRT13 knockout A-431 cell line (ab269483)
False colour image of Western blot: Anti-Cytokeratin 13 antibody [EPR3672] staining at 1/2000 dilution shown in green; Mouse anti-GAPDH antibody [6C5] (Anti-GAPDH antibody [6C5] - Loading Control ab8245) loading control staining at 1/20000 dilution shown in red. In Western blot Anti-Cytokeratin 13 antibody [EPR3672] ab133340 was shown to bind specifically to Cytokeratin 13. A band was observed at 51 kDa in wild-type A431 cell lysates with no signal observed at this size in Krt13 knockout cell line ab269483 (knockout cell lysate Human KRT13 knockout A-431 cell lysate ab269647). To generate this image wild-type and Krt13 knockout A431 cell lysates were analysed. First samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °. Blots were washed four times in TBS-T incubated with secondary antibodies for 1 h at room temperature washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776) at 1/20000 dilution.
All lanes: Western blot - Anti-Cytokeratin 13 antibody [EPR3672] (Anti-Cytokeratin 13 antibody [EPR3672] ab133340) at 1/2000 dilution
Lane 1: Wild-type A431 cell lysate at 20 µg
Lane 2: KRT13 knockout A431 cell lysate at 20 µg
Lane 2: Western blot - Human KRT13 knockout A-431 cell line (ab269483)
Performed under reducing conditions.
Predicted band size: 50 kDa
Observed band size: 51 kDa
Western blot - Human KRT13 knockout A-431 cell line (ab269483)
False colour image of Western blot: Anti-Cytokeratin 13 antibody [EPR3671] staining at 1/100000 dilution shown in green; Mouse anti-GAPDH antibody [6C5] (Anti-GAPDH antibody [6C5] - Loading Control ab8245) loading control staining at 1/20000 dilution shown in red. In Western blot Anti-Cytokeratin 13 antibody [EPR3671] ab92551 was shown to bind specifically to Cytokeratin 13. A band was observed at 51 kDa in wild-type A431 cell lysates with no signal observed at this size in Krt13 knockout cell line ab269483 (knockout cell lysate Human KRT13 knockout A-431 cell lysate ab269647). To generate this image wild-type and Krt13 knockout A431 cell lysates were analysed. First samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °. Blots were washed four times in TBS-T incubated with secondary antibodies for 1 h at room temperature washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776) at 1/20000 dilution.
All lanes: Western blot - Anti-Cytokeratin 13 antibody [EPR3671] (Anti-Cytokeratin 13 antibody [EPR3671] ab92551) at 1/100000 dilution
Lane 1: Wild-type A431 cell lysate at 20 µg
Lane 2: KRT13 knockout A431 cell lysate at 20 µg
Lane 2: Western blot - Human KRT13 knockout A-431 cell line (ab269483)
Performed under reducing conditions.
Predicted band size: 50 kDa
Observed band size: 51 kDa
Western blot - Human KRT13 knockout A-431 cell line (ab269483)
False colour image of Western blot: Anti-Cytokeratin 13 antibody [AE8] staining at 1 μg/ml shown in green; Rabbit Anti-GAPDH antibody [EPR16891] (Anti-GAPDH antibody [EPR16891] - Loading Control ab181602) loading control staining at 1/20000 dilution shown in red. In Western blot Anti-Cytokeratin 13 antibody [AE8] ab16112 was shown to bind specifically to Cytokeratin 13. A band was observed at 51 kDa in wild-type A431 cell lysates with no signal observed at this size in Krt13 knockout cell line ab269483 (knockout cell lysate Human KRT13 knockout A-431 cell lysate ab269647). To generate this image wild-type and Krt13 knockout A431 cell lysates were analysed. First samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °. Blots were washed four times in TBS-T incubated with secondary antibodies for 1 h at room temperature washed again four times then imaged. Secondary antibodies used were Goat anti-Mouse IgG H&L (IRDye® 800CW) preabsorbed (Goat anti-Mouse IgG H&L (IRDye® 800CW) preadsorbed ab216772) and Goat anti-Rabbit IgG H&L (IRDye® 680RD) preabsorbed (Goat Anti-Rabbit IgG H&L (IRDye® 680RD) preadsorbed ab216777) at 1/20000 dilution.
All lanes: Western blot - Anti-Cytokeratin 13 antibody [AE8] (Anti-Cytokeratin 13 antibody [AE8] ab16112) at 1 µg/mL
Lane 1: Wild-type A431 cell lysate at 20 µg
Lane 2: KRT13 knockout A431 cell lysate at 20 µg
Lane 2: Western blot - Human KRT13 knockout A-431 cell line (ab269483)
Performed under reducing conditions.
Predicted band size: 50 kDa
Observed band size: 51 kDa
Next Generation Sequencing - Human KRT13 knockout A-431 cell line (ab269483)
Knockout achieved by CRISPR/Cas9; X = 5 bp deletion; Frameshift: 100%
Downloads
Product protocols
- Visit the general protocols
- Visit troubleshooting
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com